Related Experiment Video
Updated: Aug 8, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Management of metastatic gastrointestinal stromal tumour in the Glivec era: a practical case-based approach
1Department of Medical Oncology, Prince of Wales Hospital, New South Wales, Australia.
Abstract:
Gastrointestinal stromal tumour is now recognized as a distinct pathological malignancy and has received much attention over the last few years. Despite almost universal resistance to chemotherapy, a novel therapy, Imatinib, which targets the KIT receptor, has changed the natural history of this disease. We have audited the first 26 consecutive patients with gastrointestinal stromal tumour treated over 4 years at a single institution. A practical guide to the management of common toxicities and drug resistance is reported with a review of the published reports. Many of the strategies used are likely to be widely applicable to the use of targeted therapies in other malignancies.
Insights
Gastrointestinal stromal tumours (GIST) are a distinct malignancy. A novel therapy, Imatinib, targeting the KIT receptor, has significantly improved patient outcomes, offering a new approach to managing this disease.
Area of Science:
- Oncology
- Gastroenterology
- Molecular Biology
Background:
- Gastrointestinal stromal tumour (GIST) is a distinct pathological malignancy.
- GIST typically shows resistance to conventional chemotherapy.
- The KIT receptor plays a crucial role in GIST development.
Purpose of the Study:
- To audit the treatment outcomes of the first 26 consecutive GIST patients at a single institution.
- To report a practical guide for managing common toxicities and drug resistance associated with GIST therapy.
- To review published literature on GIST management and targeted therapies.
Main Methods:
- Retrospective audit of 26 GIST patients treated over 4 years.
- Analysis of treatment responses, toxicities, and resistance patterns.
- Review of existing literature on GIST and targeted therapy.
Main Results:
- Imatinib therapy has altered the natural history of GIST, overcoming chemotherapy resistance.
- The study details management strategies for common toxicities and drug resistance.
- Observed outcomes in the audited patient cohort.
Conclusions:
- Imatinib is a highly effective targeted therapy for GIST.
- Effective management of toxicities and resistance is crucial for optimal patient outcomes.
- Strategies for managing GIST may be applicable to other targeted therapies in various malignancies.